BPC-157 + CJC-1295 Stack: Safety, Monitoring, and Protocol

What human data exist for each peptide?

BPC-157: FDA's July 2026 review located only five small human studies of BPC-157 and concluded there is 'insufficient clinical safety information to characterize the safety profile' [1]. A 2026 systematic review of orthopaedic and regenerative use found 3 studies with 30 patients in total, all of poor methodological quality with very low certainty, and concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [4].

CJC-1295: FDA found three published human studies, all of the DAC form and all in healthy volunteers [2]. No trial has shown a health benefit from it [2].

What does CJC-1295 do to growth hormone and IGF-I?

CJC-1295 is a long-acting analogue of growth hormone-releasing hormone (GHRH). The DAC form carries an extra unit that binds it to blood albumin, which extends its half-life from minutes to days [2][8].

In Teichman 2006 — two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61 — a single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and mean IGF-I 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days, and after multiple doses mean IGF-I stayed above baseline for up to 28 days [3]. In a separate study of single doses of 60 or 90 mcg/kg in healthy men, the frequency and size of GH pulses were unchanged, but between-pulse (trough) GH rose about 7.5-fold and mean IGF-I rose 45% [9].

FDA noted that GH and IGF-I elevation carries the risks listed on approved growth hormone labels — for example glucose intolerance and diabetes, fluid retention and tumor growth concerns — and that the human studies were short, small and mostly single-dose, so long-term safety is unknown [2].

What reactions were reported with CJC-1295?

In FDA's summary of the two Teichman trials: injection-site reactions in about 70% of treated subjects in the first study and in all treated subjects in the second; headache in 63% versus 14% on placebo; flushing, warmth and transient low blood pressure in about 30% of treated subjects in the first study; transient diarrhea; and transient dizziness and low blood pressure in two subjects. Most events were more common at 125 or 250 mcg/kg, and no serious adverse reactions were reported [2][3].

In Ionescu and Frohman 2006, single doses of 60 or 90 mcg/kg produced dose-dependent increases in heart rate and transient injection-site redness and tenderness [2].

FDA's compounding-safety page lists 'serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction' among its stated concerns [5]. FDA's briefing also says ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. Per anecdotal news reports cited by FDA, the person had chest discomfort two hours after an 11th weekly dose, an ECG showed an acute heart attack, and the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture. The data were never published, so a causal link is neither shown nor excluded [2].

What is known about the BPC-157 side?

How BPC-157 works in people is unknown. FDA says its molecular targets have not been identified and its mechanisms 'remain poorly understood', and that the reported protective effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials [1].

Human safety reporting is thin. A search of FDA's adverse-event database through December 4, 2025 turned up 3 reports, all for injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit, with no other detail; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused any of them [1].

In the small human studies FDA reviewed, no serious adverse events were reported, though the studies were short, small and gave limited safety information; in the healthy-volunteer enema studies, the most frequent events were headache and flatulence [1].

Animal signals FDA noted: in 28-day intramuscular studies BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised ALT, glucose and triglyceride levels; longer studies and cancer-risk studies were not available to the agency [1].

What did the human studies actually measure?

Each peptide was studied separately, and the measurements differ.

• CJC-1295 trials: GH and IGF-I concentrations from repeated blood sampling, taken every 20 minutes overnight in the Ionescu study [9]. The two Teichman trials ran 28 and 49 days [3].
• BPC-157 intravenous pilot: baseline blood work and vital signs before and after each infusion, with markers of heart, liver, kidney, thyroid and glucose function, on days 1 to 3. In 2 adults there was no measurable change and no reported side effect; with n=2, the study cannot establish safety [10].
• BPC-157 injections into the knee and bladder: patient-reported symptom ratings (phone recall in the knee chart review, a questionnaire in the bladder pilot), with no placebo group [11][12].

What doses appear in the published work?

Neither peptide has an approved dose, because neither is in an approved product [1][2]. The figures below are what studies used. None of them is a recommendation.

• BPC-157: rectal enema up to 2 mg/kg daily for 8 days in healthy volunteers, and 80 mg daily for 2 weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice; 10 mg injected into the bladder wall once; 10 mg then 20 mg intravenously on two days in 2 healthy adults [1].
• CJC-1295 DAC: single subcutaneous injections of about 30 to 250 mcg/kg, or 2 to 3 doses given weekly or every 2 weeks [2][3].

On routes: FDA found no human studies of BPC-157 given by mouth, subcutaneous injection, nasal spray or on the skin, and no human pharmacokinetic data for those routes [1]. After rectal enemas, BPC-157 was mostly not detectable in blood, and FDA judged it appears not to be absorbed systemically by that route [1].

Where do the two peptides stand legally?

BPC-157 is not an approved drug. No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. It sat in FDA's category 2 of bulk substances that may present significant safety risks from September 2023 until April 22, 2026, when it moved to a 'nominated but withdrawn' table after the nominating groups withdrew. Removal was not a finding of safety, and FDA's concerns stay posted: possible immunogenicity for certain routes, peptide-related impurities and characterization problems, and the statement that FDA 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [5]. BPC-157 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, so FDA's category 1 policy — under which it generally does not act against compounders when conditions are met — does not cover it [6].

In July 2026, FDA's Pharmacy Compounding Advisory Committee favored adding BPC-157 to the pharmacy bulks list, against the recommendation of FDA's own reviewers [13][1]. Its recommendation is nonbinding, BPC-157 is not on the list, and adding it requires rulemaking [13][15]. On October 28, 2026 HHS filed a draft enforcement-discretion policy naming six peptides, BPC-157 among them. It says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound them while FDA's list is developed, if the policy's conditions are met. For BPC-157 those conditions include the acetate form only, subcutaneous, intramuscular, oral or topical use, a single active ingredient, bulk substance from an FDA-registered manufacturer with a certificate of analysis, a patient-specific prescription and MedWatch reporting. The notice says it does not establish rights, is not binding, and is neither an approval nor a listing [14][15]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [15].

CJC-1295 is not in an approved product either; FDA found no approved product containing any form of it in the 12 countries it searched, and none authorized by the European Medicines Agency [2]. It is not among the six peptides in the October 2026 HHS draft policy [15], it is in none of the categories on FDA's state-licensed pharmacy list and not on its list for outsourcing facilities, so the category 1 policy does not apply [6][16]. In December 2024 FDA's Pharmacy Compounding Advisory Committee voted against adding every form of CJC-1295 — free base, acetate and each DAC form — to the pharmacy bulks list [17].

In sport, WADA's 2026 Prohibited List names BPC-157 in S0 (non-approved substances) and CJC-1295 in S2.2.4 as a growth hormone-releasing hormone analogue. Both classes are prohibited at all times, in and out of competition, and both stay named in the 2027 List [7][18].